樂普醫療拉昇漲超8% 年內獲機構扎堆調研
格隆匯2月8日丨樂普醫療(300003.SZ)盤中拉昇一度漲8.22%至31.07元,市值560億元。最新數據顯示,2021年以來,滬深兩市共424家上市公司被機構調研。機構調研榜單中共有20家公司獲100家以上機構扎堆調研,而樂普醫療最受關注,參與調研的機構多達260家。另外,公司2月3日公佈,AI事業部下屬全資子公司深圳市凱沃爾電子有限公司自主研發的具備人工智能深度學習分析算法的“多道心電圖機”(OmniECG C120 AI)於近日獲國家藥品監督管理局的註冊批准。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.